-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2023-505189-26-00
9
2023-03-28
Advanced esophageal squamous cell carcinoma
-
2024-511219-78-00
5
2023-02-28
epithelial ovarian cancer
-
2023-507233-19-00
10
2023-02-16
Treatment of IgAN
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-517382-17-00
4
2022-11-30
Newly Diagnosed Multiple Myeloma in patients eligible for stem cell tr
-
2023-507041-28-00
4
2022-11-28
Solid and Hematological Malignancies
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2022-500408-22-00
5
2022-09-14
Plaque Psoriasis
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2023-503651-10-00
7
2022-05-17
Male and female participants ≥ 18 years of age with advanced or
metast
-
2023-507119-36-00
5
2022-05-09
Malignant melanoma of the skin in patients with locally advanced and f
-
2024-511780-28-00
4
2022-05-05
Patients with presumed and previously untreated advanced stage ovarian
-
2024-511264-89-00
4
2022-04-11
Glioblastoma
-
2023-504599-10-00
4
2022-03-29
Chronic lymphocytic leukemia recurrent
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre